Abstract
AbstractIn the last few years, our understanding of disease molecular mechanisms underpinning ALS has advanced greatly, allowing the first steps in translating into clinical practice novel research findings, including gene therapy approaches. Similarly, the recent advent of assistive technologies has greatly improved the possibility of a more personalized approach to supportive and symptomatic care, in the context of an increasingly complex multidisciplinary line of actions, which remains the cornerstone of ALS management. Against this rapidly growing background, here we provide an comprehensive update on the most recent studies that have contributed towards our understanding of ALS pathogenesis, the latest results from clinical trials as well as the future directions for improving the clinical management of ALS patients.
Funder
Agenzia di Ricerca per la Sclerosi Laterale Amiotrofica
Marazzina Foundation
Publisher
Springer Science and Business Media LLC
Reference417 articles.
1. Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9:617–628
2. Xu L, Liu T, Liu L, Yao X, Chen L, Fan D, Zhan S, Wang S (2020) Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol 267:944–953
3. Riva N, Agosta F, Lunetta C, Filippi M, Quattrini A (2016) Recent advances in amyotrophic lateral sclerosis. J Neurol 263:1241–1254
4. Lloyd-Sherlock P (2000) Population ageing in developed and developing regions: implications for health policy. Soc Sci Med 51:887–895
5. Marin B, Boumédiene F, Logroscino G, Couratier P, Babron M-C, Leutenegger AL, Copetti M, Preux P-M, Beghi E (2017) Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol 46:57–74